Several studies have supported the involvement of NLRP3 inflammasome in MDD. However, most of the evidence comes from animal models. The role of NLRP3 inflammasome in BD as well as its anti-manic properties is not very clear and requires further exploration. There is evidence of anti-manic effects of P2×R7 antagonists associated with reduction in the brain levels of IL-1β and TNF-α in a murine model of mania. The involvement of other NLRP3 inflammasome expressing cells besides microglia, like astrocytes, and of other inflammasome complexes in mood disorders also deserves further investigation. Preclinical and clinical characterization of NLRP3 and other inflammasomes in mood disorders is needed before considering translational approaches, including clinical trials.
Keyphrases
- nlrp inflammasome
- bipolar disorder
- major depressive disorder
- clinical trial
- induced apoptosis
- white matter
- randomized controlled trial
- resting state
- cell therapy
- depressive symptoms
- cancer therapy
- cell proliferation
- bone marrow
- neuropathic pain
- functional connectivity
- subarachnoid hemorrhage
- case control
- double blind